Navigation Links
Carnegie Mellon develops innovative method to detect genetic causes of complex diseases
Date:8/13/2009

PITTSBURGHComputational biologists at Carnegie Mellon University have developed an analytical technique to detect the multiple genetic variations that contribute to complex disease syndromes such as diabetes, asthma and cancer, which are characterized by multiple clinical and molecular traits.

Rather than searching one at a time for genetic alterations that cause a particular symptom or trait, as in most conventional approaches, the Carnegie Mellon scientists use a statistical method that enables them to uncover genome variations underlying an entire regulatory network of genes or traits that are responsible for complex diseases.

Professor Eric P. Xing and postdoctoral scientist Seyoung Kim report today in the online journal Public Library of Science (PLoS) Genetics that their graph-guided fused lasso (GFlasso) method showed increased power in detecting gene variants associated with complex symptoms compared with other methods. In one test, GFlasso successfully detected a gene variant already implicated in severe asthma and identified two additional variants that had not previously been associated with the condition. More study of the two variants will be necessary to confirm the association, Xing and Kim said.

"We know that some of the most common and most serious diseases that plague humans are caused not by a single genetic mutation, but by a combination of many genetic and environmental factors," said Xing, an associate professor of machine learning, language technologies and computer science. "Complicating the situation is that most complex diseases have a large number of clinical traits such as various symptoms, body metrics and family history, and that genome-wide gene expression profiling can identify tens of thousands of molecular traits associated with the disease."

Typically, many of these traits are correlated. For example, high blood pressure and high body weight might share some common genetic causes. If someone tests every gene variation with every trait one pair at a time, as is the case in classical methods, the number of tests is humongous and information about the genetic causes of correlated traits is not properly used, resulting in a loss of statistical power, Xing said. "So it's unlikely we can unravel the root causes of diseases such as cancer, diabetes and asthma one gene and one trait at a time," he said. "Rather, we need tools such as GFlasso so we can look for associations between networks of genes and clinical traits."

Severe asthma, for instance, is characterized by more than 50 clinical traits, some related to environment or activity levels, some to symptoms such as wheeziness and tightness of the chest and others to lung physiology. Some of these traits are highly correlated with each other, Xing and Kim noted in the PLoS Genetics article, which suggests a common genetic basis. Their technique takes advantage of these tightly correlated traits by analyzing them jointly. This approach also helps detect genetic variations that might otherwise be missed because they have relatively subtle effects on any individual trait, but are important because they contribute to a number of correlated traits.

"This approach will provide a more comprehensive genetic and molecular view of complex diseases," Xing said, "so we can identify the genes that underlie disease processes, understand the role of genes in determining the severity of disease and develop improved methods for diagnosing disease."

Xing, a member of the Ray and Stephanie Lane Center for Computational Biology at Carnegie Mellon, is working with colleagues at the University of Pittsburgh School of Medicine and Harvard Medical School to use GFlasso to study severe asthma as part of an ongoing study sponsored by the National Institutes of Health.


'/>"/>

Contact: Byron Spice
bspice@cs.cmu.edu
412-268-9068
Carnegie Mellon University
Source:Eurekalert

Related biology news :

1. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
2. Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing
3. Carnegie Mellon scientist uses mass spectrometer to weigh virus particle, von Willebrand factor
4. Carnegie Mellon, Pitt Team to study psychosocial stress
5. Mellon awards Carnegie Grant for Ecological Monitoring in South Africa
6. Carnegie Mellon researchers to develop new drug delivery system
7. Carnegie Mellon students win contest
8. Novel mechanism for long-term learning identified by Carnegie Mellon researchers
9. U. Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica
10. Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design
11. Carnegie Mellon receives $1.85 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology: